Affinity Maturation of an Epidermal Growth Factor Receptor Targeting Human Monoclonal Antibody ER414 by CDR Mutation.
- Author:
Ki Hwan CHANG
1
;
Min Soo KIM
;
Gwang Won HONG
;
Mi Sun SEO
;
Yong Nam SHIN
;
Se Ho KIM
Author Information
- Publication Type:In Vitro ; Original Article
- Keywords: Affinity maturation; EGFR; Epitope; Phage-display; CDR randomization; Tyrosine phosphorylation
- MeSH: Amino Acids; Animals; Antibodies; Antibodies, Monoclonal, Humanized; Bacteriophages; Cell Death; Cetuximab; Clone Cells; Deoxycytidine; Epidermal Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Mice; Phosphorylation; Receptor, Epidermal Growth Factor; Tyrosine
- From:Immune Network 2012;12(4):155-164
- CountryRepublic of Korea
- Language:English
- Abstract: It is well established that blocking the interaction of EGFR with growth factors leads to the arrest of tumor growth, resulting in tumor cell death. ER414 is a human monoclonal antibody (mAb) derived by guided selection of the mouse mAb A13. The ER414 exhibited a ~17-fold lower affinity and, as a result, lower efficacy of inhibition of the EGF-mediated tyrosine phosphorylation of EGFR when compared with mAb A13 and cetuximab. We performed a stepwise in vitro affinity maturation to improve the affinity of ER414. We obtained a 3D model of ER414 to identify the amino acids in the CDRs that needed to be mutated. Clones were selected from the phage library with randomized amino acids in the CDRs and substitution of amino acids in the HCDR3 and LCDR1 of ER414 led to improved affinity. A clone, H3-14, with a ~20-fold increased affinity, was selected from the HCDR3 randomized library. Then three clones, ER2, ER78 and ER79, were selected from the LCDR1 randomized library based on the H3-14 but did not show further increased affinities compared to that of H3-14. Of the three, ER2 was chosen for further characterization due to its better expression than others. We successfully performed affinity maturation of ER414 and obtained antibodies with a similar affinity as cetuximab. And antibody from an affinity maturation inhibits the EGF-mediated tyrosine phosphorylation of EGFR in a manner similar to cetuximab.
